Business Description
Kyverna Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US5019761049
Description
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 35.2 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | -26.59 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.37 | |||||
| 9-Day RSI | 36.42 | |||||
| 14-Day RSI | 39.36 | |||||
| 6-1 Month Momentum % | -43.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.5 | |||||
| Quick Ratio | 10.5 | |||||
| Cash Ratio | 10.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -198.36 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -73.38 | |||||
| ROA % | -43.91 | |||||
| ROIC % | -573.87 | |||||
| ROC (Joel Greenblatt) % | -947.28 | |||||
| ROCE % | -48.17 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.57 | |||||
| Price-to-Tangible-Book | 0.57 | |||||
| EV-to-EBIT | 1.27 | |||||
| EV-to-Forward-EBIT | -0.1 | |||||
| EV-to-EBITDA | 1.3 | |||||
| EV-to-FCF | 1.44 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.59 | |||||
| Earnings Yield (Greenblatt) % | 78.74 | |||||
| FCF Yield % | -56.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KYTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kyverna Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.096 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 39.36 | ||
| 14-Day ATR ($) | 0.449034 | ||
| 20-Day SMA ($) | 4.795 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 3.625 - 35.06 | ||
| Shares Outstanding (Mil) | 43.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kyverna Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kyverna Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kyverna Therapeutics Inc Frequently Asked Questions
What is Kyverna Therapeutics Inc(KYTX)'s stock price today?
The current price of KYTX is $3.92. The 52 week high of KYTX is $35.06 and 52 week low is $3.63.
When is next earnings date of Kyverna Therapeutics Inc(KYTX)?
The next earnings date of Kyverna Therapeutics Inc(KYTX) is 2025-02-28 Est..
Does Kyverna Therapeutics Inc(KYTX) pay dividends? If so, how much?
Kyverna Therapeutics Inc(KYTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers